To remember
- The use of 5α-reductase inhibitors (5-ARI) was associated with a reduced risk of adenocarcinoma of the esophagus or cardia in obese or diabetic patients.
Why is this important?
- This is one of the first studies to assess associations between 5-ARI use and the risk of esophageal cancer and gastric cancer.